[HTML][HTML] First-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers
BI Sikic, N Lakhani, A Patnaik, SA Shah… - Journal of Clinical …, 2019 - ncbi.nlm.nih.gov
BI Sikic, N Lakhani, A Patnaik, SA Shah, SR Chandana, D Rasco, AD Colevas, T O'Rourke…
Journal of Clinical Oncology, 2019•ncbi.nlm.nih.govFirst-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients
With Advanced Cancers - PMC Back to Top Skip to main content NIH NLM Logo Access keys
NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search PMC Full-Text
Archive Search in PMC Advanced Search User Guide Journal List J Clin Oncol PMC7186585
Other Formats PubReader PDF (927K) Actions Cite Collections Share Permalink Copy
RESOURCES Similar articles Cited by other articles Links to NCBI Databases Journal List J …
With Advanced Cancers - PMC Back to Top Skip to main content NIH NLM Logo Access keys
NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search PMC Full-Text
Archive Search in PMC Advanced Search User Guide Journal List J Clin Oncol PMC7186585
Other Formats PubReader PDF (927K) Actions Cite Collections Share Permalink Copy
RESOURCES Similar articles Cited by other articles Links to NCBI Databases Journal List J …
Abstract
PURPOSE
To evaluate the safety, pharmacokinetics, and pharmacodynamics of Hu5F9-G4 (5F9), a humanized IgG4 antibody that targets CD47 to enable phagocytosis.
ncbi.nlm.nih.gov